The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection
Open accessAbstract
Although mononuclear cell infiltration is a hallmark of cellular rejection of a vascularized allograft, efforts to inhibit rejection by blocking leukocyte-endothelial cell adhesion have proved largely unsuccessful, perhaps in part because of persistent generation of chemokines within rejecting grafts. We now provide, to our knowledge, the first evidence that in vivo blockade of specific chemokine receptors is of therapeutic significance in organ transplantation. Inbred mice with a targeted deletion of the chemokine receptor CCR1 showed significant prolongation of allograft survival in 4 models. First, cardiac allografts across a class II mismatch were rejected by CCR1(+/+) recipients but were accepted permanently by CCR1(-/-) recipients. Second, CCR1(-/-) mice rejected completely class I- and class II-mismatched BALB/c cardiac allografts more slowly than control mice. Third, levels of cyclosporin A that had marginal effects in CCR1(+/+) mice resulted in permanent allograft acceptance in CCR1(-/-) recipients. These latter allografts showed no sign of chronic rejection 50-200 days after transplantation, and transfer of CD4(+) splenic T cells from these mice to naive allograft recipients significantly prolonged allograft survival, whereas cells from CCR1(+/+) mice conferred no such benefit. Finally, both CCR1(+/+) and CCR1(-/-) allograft recipients, when treated with a mAb to CD4, showed permanent engraftment, but these allografts showed florid chronic rejection in the former strain and were normal in CCR1(-/-) mice. We conclude that therapies to block CCR1/ligand interactions may prove useful in preventing acute and chronic rejection clinically.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gerard, C., Frossard, J. L., Bhatia, M., Saluja, A., Gerard, N. P., Lu, B., & Steer, M. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119734 · Cited by 212
Self-citation
Cited by
International Union of Pharmacology. XXII. Nomenclature for Chemokine Receptors
Murphy, P. M., Baggiolini, M., Charo, I. F., Hébert, C. A., Horuk, R., Matsushima, K., Miller, L. H., Oppenheim, J. J., & Power, C. A. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01439-x · Cited by 1,817
Gerard, C., & Rollins, B. J. (2001) · Nature Immunology · doi:10.1038/84209 · Cited by 1,357
Self-citationChemokines: immunology's high impact factors
Mackay, C. R. (2001) · Nature Immunology · doi:10.1038/84298 · Cited by 845
Chemokine receptors: multifaceted therapeutic targets
Proudfoot, A. E. I. (2002) · Nature Reviews Immunology · doi:10.1038/nri722 · Cited by 752
Chemokines as regulators of T cell differentiation
Luther, S. A., & Cyster, J. G. (2001) · Nature Immunology · doi:10.1038/84205 · Cited by 736
Metadata
- Authors
- Gao, W., Topham, P. S., King, J. A., Smiley, S. T., Csizmadia, V., Lu, B., Gerard, C. J., & Hancock, W. W.
- Venue
- Journal of Clinical Investigation
- Published
- 2000-01-01
- Volume
- 105
- Issue
- 1
- Pages
- 35-44
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1985277568
- Cited by
- 250
- References
- 1
- FWCI
- 34.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection. https://app.cochat.ai/papers/10.1172/jci8126
- The paper
- Gao, W., Topham, P. S., King, J. A., Smiley, S. T., Csizmadia, V., Lu, B., Gerard, C. J., & Hancock, W. W. (2000). Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection. Journal of Clinical Investigation. https://doi.org/10.1172/jci8126
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.